Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRONTiER: nivolumab with neoadjuvant CF, DCF, or FLOT for locally advanced thoracic esophageal cancer
jRCT2031180172Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- May 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of nivolumab, fluorouracil, cisplatin, docetaxel, levoleucovorin and 1 more in esophageal cancer (3 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Dose-limiting toxicity expression rate. Started May 2019; status: active, not recruiting.
02
Drugs
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on jRCT2031180172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031180172.